Search
for
Sort by
Research 121–150 of 554
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
- Janus kinase inhibitors for alopecia areata
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- European expert consensus statement on the systemic treatment of alopecia areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- Alopecia areata: from pathophysiology to therapeutic innovation
- Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- Alopecia Areata: Current and Emerging Therapies
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Development and Therapeutic Evaluation of a Uniform Lymph Node Cell Transfer Model of Alopecia Areata 2256823
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study
- Success of Deuruxolitinib (Leqselvi™) in Extensively Treatment-Resistant Alopecia Universalis: A Case Report
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Alopecia areata: current concepts
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- A Comprehensive Review on Alopecia Areata and its Pathophysiology, Diagnosis, Treatment, and Psychosocial Impact